Proceedings from the 2nd European Clinical Consensus Conference for device-based therapies for hypertension: state of the art and considerations for the future

Abstract

[1]  A. Konradi,et al.  [PP.15.34] PULSE WAVE VELOCITY AND RENAL RESISTIVE INDEX IN PATEINTS WITH RESISTANT HYPERTENSION: RELATION TO BLOOD PRESSURE CHANGES AFTER RENAL DENERVATION , 2017 .

[2]  Deepak L. Bhatt,et al.  Reduced blood pressure-lowering effect of catheter-based renal denervation in patients with isolated systolic hypertension: data from SYMPLICITY HTN-3 and the Global SYMPLICITY Registry , 2016, European heart journal.

[3]  P. Sobotka,et al.  Interventional procedures and future drug therapy for hypertension , 2016, European heart journal.

[4]  S. Achenbach,et al.  Effect of Arteriovenous Anastomosis on Blood Pressure Reduction in Patients With Isolated Systolic Hypertension Compared With Combined Hypertension , 2016, Journal of the American Heart Association.

[5]  Deepak L. Bhatt,et al.  Regression to the Mean in SYMPLICITY HTN-3: Implications for Design and Reporting of Future Trials. , 2016, Journal of the American College of Cardiology.

[6]  M. Böhm,et al.  Catheter-based radio-frequency renal nerve denervation lowers blood pressure in obese hypertensive swine model , 2016, Journal of hypertension.

[7]  J. Václavík,et al.  [OP.7D.09] THE ROLE OF ADDING SPIRONOLACTONE AND RENAL DENERVATION IN TRUE RESISTANT HYPERTENSION. ONE-YEAR OUTCOMES OF RANDOMIZED PRAGUE-15 STUDY , 2016, Journal of hypertension.

[8]  J. Staessen,et al.  Renal Nerve Stimulation–Induced Blood Pressure Changes Predict Ambulatory Blood Pressure Response After Renal Denervation , 2016, Hypertension.

[9]  G. Parati,et al.  Effects of blood pressure lowering treatment in hypertension: 8. Outcome reductions vs. discontinuations because of adverse drug events – meta-analyses of randomized trials , 2016, Journal of hypertension.

[10]  Manish Saxena,et al.  Device-based Therapy for Hypertension , 2016, Current Hypertension Reports.

[11]  P. McFarlane,et al.  Hypertension Canada's 2016 Canadian Hypertension Education Program Guidelines for Blood Pressure Measurement, Diagnosis, Assessment of Risk, Prevention, and Treatment of Hypertension. , 2016, The Canadian journal of cardiology.

[12]  G. Mancia,et al.  Unattended Blood Pressure Measurements in the Systolic Blood Pressure Intervention Trial: Implications for Entry and Achieved Blood Pressure Values Compared With Other Trials , 2016, Hypertension.

[13]  P. Levy,et al.  New Approaches to Evaluating and Monitoring Blood Pressure , 2016, Current Hypertension Reports.

[14]  G. Parati,et al.  Effects of blood pressure lowering on outcome incidence in hypertension: 7. Effects of more vs. less intensive blood pressure lowering and different achieved blood pressure levels – updated overview and meta-analyses of randomized trials , 2016, Journal of hypertension.

[15]  S. Anderson,et al.  Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis , 2016, The Lancet.

[16]  G. Mancia,et al.  No evidence for a J-shaped curve in treated hypertensive patients with increased cardiovascular risk: The VALUE trial , 2016, Blood pressure.

[17]  Otto Mayer,et al.  Automated compared to manual office blood pressure and to home blood pressure in hypertensive patients , 2016, Blood pressure.

[18]  M. Uder,et al.  Adherence to Antihypertensive Medication in Treatment‐Resistant Hypertension Undergoing Renal Denervation , 2016, Journal of the American Heart Association.

[19]  J. Václavík,et al.  Role of Adding Spironolactone and Renal Denervation in True Resistant Hypertension: One-Year Outcomes of Randomized PRAGUE-15 Study , 2016, Hypertension.

[20]  Jiang He,et al.  Global Disparities of Hypertension Prevalence and Control: A Systematic Analysis of Population-Based Studies From 90 Countries. , 2015, Circulation.

[21]  S. Pocock,et al.  The SPYRAL HTN Global Clinical Trial Program: Rationale and design for studies of renal denervation in the absence (SPYRAL HTN OFF-MED) and presence (SPYRAL HTN ON-MED) of antihypertensive medications. , 2016, American heart journal.

[22]  C. Escobar Cervantes,et al.  [A randomized trial of intensive versus standard blood pressure control]. , 2016, Semergen.

[23]  Isla Mackenzie,et al.  Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial , 2015, The Lancet.

[24]  M. Seyfarth,et al.  Intraprocedural reduction of the veno-arterial norepinephrine gradient correlates with blood pressure response after renal denervation. , 2015, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

[25]  G. Bakris,et al.  The double challenge of resistant hypertension and chronic kidney disease , 2015, The Lancet.

[26]  G. Chatellier,et al.  Proceedings from the European clinical consensus conference for renal denervation: considerations on future clinical trial design. , 2015, European heart journal.

[27]  M. Burnier,et al.  Blood pressure reductions following catheter-based renal denervation are not related to improvements in adherence to antihypertensive drugs measured by urine/plasma toxicological analysis , 2015, Clinical Research in Cardiology.

[28]  P. Gosse,et al.  Optimum and stepped care standardised antihypertensive treatment with or without renal denervation for resistant hypertension (DENERHTN): a multicentre, open-label, randomised controlled trial , 2015, The Lancet.

[29]  A. Tzafriri,et al.  Arterial microanatomy determines the success of energy-based renal denervation in controlling hypertension , 2015, Science Translational Medicine.

[30]  H. Krum,et al.  Magnitude of Blood Pressure Reduction in the Placebo Arms of Modern Hypertension Trials: Implications for Trials of Renal Denervation , 2015, Hypertension.

[31]  C. May,et al.  Reinnervation of Renal Afferent and Efferent Nerves at 5.5 and 11 Months After Catheter-Based Radiofrequency Renal Denervation In Sheep , 2015, Hypertension.

[32]  M. Böhm,et al.  Reduced Effect of Percutaneous Renal Denervation on Blood Pressure in Patients With Isolated Systolic Hypertension , 2015, Hypertension.

[33]  S. Yusuf,et al.  Systolic and Diastolic Blood Pressure Changes in Relation With Myocardial Infarction and Stroke in Patients With Coronary Artery Disease , 2015, Hypertension.

[34]  G. Parati,et al.  Effects of blood pressure lowering on outcome incidence in hypertension. 1. Overview, meta-analyses, and meta-regression analyses of randomized trials , 2014, Journal of hypertension.

[35]  R. Schmieder,et al.  Disproportional Decrease in Office Blood Pressure Compared With 24-Hour Ambulatory Blood Pressure With Antihypertensive Treatment: Dependency on Pretreatment Blood Pressure Levels , 2014, Hypertension.

[36]  F. Ikeno,et al.  TCT-422 Transluminal Imaging of Renal Nerves using Optical Coherence Tomography , 2014 .

[37]  M. Böhm,et al.  Renal denervation for the treatment of cardiovascular high risk-hypertension or beyond? , 2014, Circulation research.

[38]  Geoffrey A Head,et al.  European Society of Hypertension practice guidelines for ambulatory blood pressure monitoring. , 2014, Journal of hypertension.

[39]  Deepak L. Bhatt,et al.  Refining calcium test for diagnosis of medullary thyroid cancer: cutoffs, procedures and safety , 2014, The New England journal of medicine.

[40]  G. Bakris,et al.  Baroreflex activation therapy safely reduces blood pressure for at least five years in a large resistant hypertension cohort , 2014 .

[41]  Michael Böhm,et al.  Percutaneous renal denervation in patients with treatment-resistant hypertension: final 3-year report of the Symplicity HTN-1 study , 2014, The Lancet.

[42]  J. Staessen,et al.  Blood pressure changes after renal denervation at 10 European expert centers , 2013, Journal of Human Hypertension.

[43]  F. Mahfoud,et al.  Transluminal Imaging of Renal Nerves using Optical Coherence Tomography , 2014 .

[44]  A. Arboix,et al.  Blood-pressure targets in patients with recent lacunar stroke: the SPS3 randomised trial , 2013 .

[45]  Jeroen J. Bax,et al.  2007 ESH-ESC Guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). , 2007, Blood pressure.

[46]  B. Williams,et al.  Expert consensus document from the European Society of Cardiology on catheter-based renal denervation. , 2013, European heart journal.

[47]  S. Toennes,et al.  Resistant hypertension? Assessment of adherence by toxicological urine analysis , 2013, Journal of hypertension.

[48]  Michael Böhm,et al.  2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). , 2007, Journal of hypertension.

[49]  C. McKevitt,et al.  Lay perspectives on hypertension and drug adherence: systematic review of qualitative research , 2012, BMJ : British Medical Journal.

[50]  G. Bakris,et al.  Baroreflex activation therapy lowers blood pressure in patients with resistant hypertension: results from the double-blind, randomized, placebo-controlled rheos pivotal trial. , 2011, Journal of the American College of Cardiology.

[51]  A. Logan.  Hypertension in aging patients , 2011, Expert review of cardiovascular therapy.

[52]  Kevin A Peterson,et al.  Effects of Intensive Blood-Pressure Control in Type 2 Diabetes Mellitus , 2011 .

[53]  Heejung Bang,et al.  Assessment of blinding in clinical trials. , 2004, Controlled clinical trials.

[54]  M. Nieminen,et al.  The Losartan Intervention For Endpoint reduction (LIFE) in Hypertension study: rationale, design, and methods. The LIFE Study Group. , 1997, American journal of hypertension.

[55]  M. Nieminen,et al.  H35: Baseline characteristics of the life (Losartan intervention for endpoint reduction) in hypertension study , 1997 .

[56]  Effects of treatment on morbidity in hypertension. Results in patients with diastolic blood pressures averaging 115 through 129 mm Hg. , 1967, JAMA.

[57]  W. Kirkendall,et al.  Surgical treatment of hypertension. , 1963, Advances in surgery.